公开(公告)号：US20140134142A1

公开(公告)日：2014-05-15

申请号：US14018021

申请日：2013-09-04

Applicant: CELLECTIS

Inventor： Julianne Smith ,  Andrew Scharenberg ,  Cecile Mannioui ,  Justin Eyquem

IPC: C07K16/28

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections.

Abstract translation: 本发明涉及称为多链CAR的新一代嵌合抗原受体（CAR）。 旨在将免疫细胞特异性和反应性转向使用配体结合结构域性质的选定靶标的这样的CAR在不同跨膜多肽中包含分离的细胞外配体结合和信号结构域。 信号域被设计为在并置位置组装，其形成更接近天然受体的柔性结构，其赋予最佳信号转导。 本发明包括多核苷酸，编码所述多链CAR的载体和在其表面表达它们的分离细胞，特别是其用于免疫治疗。 本发明开创了治疗癌症和病毒感染的有效过继性免疫治疗策略的途径。

公开(公告)号：US10342829B2

公开(公告)日：2019-07-09

申请号：US14018021

申请日：2013-09-04

Applicant: CELLECTIS

Inventor： Julianne Smith ,  Andrew Scharenberg ,  Cecile Mannioui ,  Justin Eyquem

IPC: A61K35/17 ,  A61K38/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. 91The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections.